A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer

This publication has 15 references indexed in Scilit: